The vaccine market in the UK is expected to reach a projected revenue of US$ 4,988.5 million by 2033. A compound annual growth rate of 5.8% is expected of the UK vaccine market from 2026 to 2033.
The UK vaccine market generated a revenue of USD 3,137.2 million in 2025 and is expected to reach USD 4,988.5 million by 2033.
The UK market is expected to grow at a CAGR of 5.8% from 2026 to 2033.
In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
Vaccine market data book summary
Market revenue in 2025
USD 3,137.2 million
Market revenue in 2033
USD 4,988.5 million
Growth rate
5.8% (CAGR from 2026 to 2033)
Largest segment
Viral vaccines
Fastest growing segment
Other Indication
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication
Key market players worldwide
Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc
Other key industry trends
In terms of revenue, UK accounted for 4.3% of the global vaccine market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany vaccine market is projected to lead the regional market in terms of revenue in 2033.
France is the fastest growing regional market in Europe and is projected to reach USD 3,784.9 million by 2033.
The vaccine market in the UK is one of the major markets in the region. High vaccine uptake against the flu, better immunization programs, favorable government initiatives, and increased R&D activities in the country are driving the market growth. In addition, the high disease burden and significant government interventions in vaccination programs are some of the factors driving the market.
For instance, in September 2018, Public Health England announced new flu vaccination recommendations for individuals aged more than 65. The authority recommended the adjuvanted trivalent influenza vaccine to people with higher influenza risk.
Moreover, ongoing collaborations between leading participants and governments to maintain a robust vaccine supply are propelling market growth. For instance, in December 2022, Moderna announced its plans to invest in mRNA R&D in the UK and establish a new vaccine development center with a capacity to manufacture up to 250 million vaccines a year.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Vaccine Market Outlook will help companies and investors design strategic landscapes.
Viral Vaccines was the largest segment with a revenue share of 64.78% in 2025.
Horizon Databook has segmented the U.K. vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
The vaccine market in the UK is one of the major markets in the region. High vaccine uptake against the flu, better immunization programs, favorable government initiatives, and increased R&D activities in the country are driving the market growth. In addition, the high disease burden and significant government interventions in vaccination programs are some of the factors driving the market.
For instance, in September 2018, Public Health England announced new flu vaccination recommendations for individuals aged more than 65. The authority recommended the adjuvanted trivalent influenza vaccine to people with higher influenza risk.
Moreover, ongoing collaborations between leading participants and governments to maintain a robust vaccine supply are propelling market growth. For instance, in December 2022, Moderna announced its plans to invest in mRNA R&D in the UK and establish a new vaccine development center with a capacity to manufacture up to 250 million vaccines a year.
U.K. Vaccine Market Indication Outlook (Revenue, USD Million , 2021-2033)
Viral Vaccines
Bacterial Vaccines
Cancer Vaccines
Allergy Vaccines
Other Indication
U.K. Vaccine Market Type Outlook (Revenue, USD Million , 2021-2033)
Subunit Vaccines
Inactivated
Live Attenuated
mRNA Vaccines
Viral Vector Vaccines
U.K. Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Parenteral
Nasal
U.K. Vaccine Market Age Group Outlook (Revenue, USD Million , 2021-2033)
Pediatric Age Group
Adult Age Group
U.K. Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital & Retail Pharmacies
Government Suppliers
Others Distribution Channel
Reasons to subscribe to Vaccine Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Vaccine Market Outlook databook
Our clientele includes a mix of Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Vaccine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.